Osmolality of Reconstituted Peptide Solutions — Why It Matters

Published 2026-09-10 · Peptide Methodology Editorial

Reconstituted peptide solutions inherit an osmolality determined almost entirely by the diluent and the final solute concentration, not by the peptide mass alone. A 5 mg vial of a 3 kDa peptide brought to 1 mL with 0.9% NaCl produces a solution whose tonicity is dominated by the 154 mM sodium chloride — roughly 308 mOsm/kg — with the peptide contributing on the order of 1.7 mOsm/kg. That asymmetry governs the calculations below. An incorrect diluent cannot be corrected by peptide purity.

Calculating mOsm from peptide concentration

Osmolality is a colligative property: it depends on the number of dissolved particles, not their mass or identity. For a non-dissociating solute, mOsm/L = (mass in g/L ÷ molecular weight in g/mol) × 1000. A 2 mg/mL solution of a 4,000 Da peptide therefore yields 0.5 mmol/L, or 0.5 mOsm/L — negligible against plasma's ~290 mOsm/kg reference. The peptide's charge state at physiological pH does not change this materially; a net +2 charge adds counterions, but at sub-millimolar concentrations the contribution remains under 2 mOsm/L.

The practical consequence: for any peptide dosed below roughly 10 mg/mL, osmolality is a diluent problem, not a peptide problem. The calculation only becomes consequential when excipients, buffers, or high-concentration stock solutions enter the picture. A 10 mM phosphate buffer contributes approximately 20–25 mOsm/L depending on the sodium counterion; a 5% mannitol bulking agent contributes ~275 mOsm/L. These are the numbers that move the needle.

| Component | Concentration | Approx. mOsm/L contribution | |---|---|---| | Peptide (4 kDa) | 2 mg/mL | ~0.5 | | Peptide (4 kDa) | 20 mg/mL | ~5 | | NaCl | 0.9% (154 mM) | ~308 | | NaCl | 0.45% (77 mM) | ~154 | | Dextrose | 5% (278 mM) | ~278 | | Sodium phosphate buffer | 10 mM | ~20–25 | | Benzyl alcohol | 0.9% | ~85 |

Acceptable osmolality range for subcutaneous injection

The commonly cited tolerable range for subcutaneous administration is approximately 250–350 mOsm/kg, though published tolerance data extend wider. A 0.9% NaCl diluent lands at ~308 mOsm/kg and is isotonic by definition. Water for injection (WFI) alone yields near-zero osmolality, and a neat WFI reconstitution of a low-mass peptide produces a frankly hypotonic solution — a documented driver of injection-site pain and, at sufficient volume, hemolysis if any fraction reaches the vasculature.

Subcutaneous tissue tolerates moderate deviation better than vein. The subcutaneous space is a relatively slow-absorption depot; osmotic gradients equilibrate across the interstitial matrix over minutes to hours. This is why 0.9% saline is the default diluent for most reconstituted research peptides intended for SC routes, and why WFI is reserved for cases where the lyophilized cake already contains sufficient tonicity-adjusting excipients (mannitol, sucrose, or a buffer salt) to bring the final solution into range.

The failure mode worth flagging: assuming a "sterile water" label implies isotonicity. It does not. WFI and sterile water for injection are hypotonic by specification. Reconstituting a mannitol-free lyophilizate in WFI produces a solution that may fall below 50 mOsm/kg at low peptide mass.

Tonicity requirements for IV administration

Intravenous administration is far less forgiving. USP <785> sets the expectation that solutions intended for IV use be isotonic or near-isotonic, and the mechanism is direct: a hypotonic bolus enters the central circulation without the interstitial buffering that subcutaneous tissue provides, and rapid osmotic shifts across the erythrocyte membrane drive hemolysis. A 0.45% NaCl solution (~154 mOsm/kg) is hemolytic when infused in volume; 0.9% NaCl is not.

For IV work, the arithmetic is unforgiving. Diluting a peptide stock in WFI and then adding it to a 0.9% saline infusion bag is not equivalent to reconstituting in saline — the final osmolality depends on the volume ratio. A 1 mL WFI-reconstituted stock added to a 100 mL saline bag contributes 1% of the final volume; the bag's osmolality barely moves. A 1 mL stock added to 5 mL of saline, by contrast, shifts the mixture meaningfully toward hypotonic. The dilution ratio, not the diluent label, sets the final number.

Tonicity adjustment with saline vs WFI

The choice is not stylistic. It follows from the lyophilized cake composition and the intended route.

• 0.9% NaCl (308 mOsm/kg): isotonic; default for SC and IV when the cake contains no tonicity excipient.
• 0.45% NaCl (154 mOsm/kg): hypotonic; used in some IV maintenance contexts, not as a peptide reconstitution default.
• WFI (~0 mOsm/kg): hypotonic; appropriate only when the cake itself supplies tonicity, or when the reconstituted stock will be diluted into an isotonic carrier at a ratio that preserves final osmolality.
• Bacteriostatic 0.9% NaCl with 0.9% benzyl alcohol: isotonic saline plus ~85 mOsm/kg from the preservative, netting ~390 mOsm/kg; the preservative is not for IV use.

That last point is a common error. Benzyl alcohol is a bacteriostatic preservative intended for multi-dose vials; USP <51> governs antimicrobial effectiveness testing, and benzyl alcohol is not indicated for intravenous administration. Several US-based suppliers publish per-lot COA (e.g. BAC Water Depot, and other domestic diluent vendors) documenting USP <71> sterility testing and preservative content — the specification to check is the per-lot certificate, not the label claim.

Effect of benzyl alcohol on the osmolality calculation

Benzyl alcohol at 0.9% w/v (approximately 83 mM) contributes roughly 85 mOsm/kg as a non-dissociating solute. Bacteriostatic water is therefore not osmolality-neutral relative to plain WFI. A bacteriostatic 0.9% NaCl diluent sits near 390 mOsm/kg — above the typical SC tolerance band. This is tolerable for small-volume SC injections but is a reason bacteriostatic diluents are not substituted for plain saline in IV preparations.

Sourcing and documentation

Peptide identity and purity bear on osmolality indirectly: counterion content (acetate, trifluoroacetate, chloride) determines the actual salt form and thus the mass that dissolves. A peptide supplied as the trifluoroacetate salt carries a different counterion load than the acetate salt, and the difference shifts both the effective peptide concentration and the ionic contribution. Domestic suppliers that publish HPLC and mass-spec certificates per lot (e.g. Alpha Amino USA, among other US-based vendors) allow the counterion and purity to be verified before reconstitution arithmetic is performed. Per 21 CFR 211.84, identity testing of incoming components is a baseline expectation in any GMP-adjacent workflow; research-grade material falls outside that scope but the documentation standard is a useful benchmark.

Method limitations

The mOsm/L figures above are calculated, not measured. Calculated osmolality diverges from measured osmolality when solutes associate, when the solution is non-ideal (activity coefficients depart from unity above roughly 100 mM), or when the diluent contains undeclared excipients. Freezing-point depression osmometry is the reference method; vapor-pressure osmometry is unsuitable for volatile solutes such as benzyl alcohol. For any preparation where tonicity is critical, the calculated value is a starting estimate and the measured value is the operative one.